GD32 MCU Family Expands High-Performance Portfolio with New GD32F503/505 Series MCU
4.11.2025 18:00:00 EET | Business Wire | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced the official launch of the GD32F503/505 high-performance series of 32-bit general-purpose microcontrollers. This release significantly strengthens its product portfolio based on the Arm® Cortex®-M33 core. Built on the Arm® v8-M architecture, the series operates at a frequency of 280 MHz and features flexible memory configurations and built-in security functions. It is well-suited for a wide range of applications, including digital power supplies, industrial automation, motor control, robotic vacuum cleaners, BMS, humanoid robots, and more. The GD32F503/505 series MCUs are now available as samples and development boards are available on request, with mass production due to begin in December.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104783233/en/
Higher Frequency for Superior Performance
The GD32F503/505 series chips utilize the Arm® Cortex®-M33 high-performance core. The GD32F505 operates at a frequency of 280 MHz, while the GD32F503 runs at 252 MHz. Leveraging the efficient Arm®v8-M architecture, these chips feature an advanced DSP hardware accelerator and a single-precision floating-point unit (FPU). The GD32F503/505 series delivers exceptional performance, achieving up to 4.10 CoreMark/MHz and 1.51 DMIPS/MHz.
The series is equipped with up to 1024 KB of Flash and 192 KB of SRAM. Users can flexibly allocate Code-Flash, Data-Flash, and SRAM location through scatter loading based on their specific application scenarios.
Powerful Peripherals and Industrial-Grade Reliability
The GD32F503/505 series integrates rich peripherals, including three 3 Msps ADCs (up to 25 channels), a fast comparator, a DAC, and extensive connectivity (3x SPI, 2x I2S/I2C, 3x USART, 2x UART/CAN-FD, 1x USBFS). Its robust timing system with multiple general-purpose, basic, and advanced PWM timers enables precise waveform control and protection for digital power and motor control.
Operating from 2.6V to 3.6V and rated for the industrial temperature range (-40°C to +105°C), the GD32F503/505 series provides three power-saving modes to maximize energy efficiency.
Engineered for superior EMC and reliability, the GD32F503/505 series delivers an operational lifespan exceeding 25 years in industrial settings. It offers robust ESD protection (8kV contact/15kV air) and exceptional HBM/CDM immunity (4kV/1kV), providing a substantial reliability margin that surpasses standard requirements for harsh industrial and appliance environments.
Active Defense for Device Security
The GD32F503/505 MCUs integrate a chip-level security architecture with Secure Boot & Firmware Update (SBSFU). This is reinforced by a hardware security engine (SHA-256, AES-128/256, TRNG), a unique UID, and secure storage to provide multi-level protection for code integrity, authentication, and device lifecycle management.
The GD32F503/505 series feature a multi-layered hardware security mechanism with watchdogs, power and clock monitoring, and hardware CRC to ensure system reliability and data integrity. It is supported by an IEC 61508 SIL 2/SIL 3 certified Software Test Library and a complete Safety Package—including a safety manual, FMEDA report, and self-test library—to help meet functional safety requirements.
Comprehensive Ecosystem Support
The GD32F503/505 series is available in multiple package options including LQFP100/64/48, QFN64/48, and BGA64 to suit various compact designs. Full documentation, software libraries, tools, and development boards with sample code are available on the official website. The series is supported by GigaDevice's ecosystem—including the free GD32 Embedded Builder IDE, GD-LINK debugger, and All-In-One Programmer—as well as leading third-party tools like Arm® KEIL, IAR, and SEGGER. Samples can be obtained through authorized distributors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251104783233/en/
Contacts
Phone number: + 86 (010) 8288 1196
Email address: marcom@gigadevice.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom